Does Mounjaro Make You Cold? The Metabolic Shift Behind Temperature Sensitivity

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro causes cold sensitivity in 18-24% of patients through three mechanisms: reduced metabolic rate during calorie restriction, loss of insulating body fat, and potential thyroid hormone changes
• Cold intolerance typically peaks between weeks 8 and 16 of treatment, when weight loss is most rapid, and often improves after 20-24 weeks at maintenance dose
• Persistent coldness with additional symptoms (severe fatigue, hair loss, constipation, depression) may indicate thyroid dysfunction and requires lab work
• Most cold sensitivity resolves without intervention as the body adapts to new metabolic baseline and weight stabilizes

Direct answer (40-60 words)

Yes, Mounjaro (tirzepatide) commonly causes cold sensitivity in 18-24% of patients. The mechanism is threefold: reduced metabolic rate during calorie restriction, loss of insulating subcutaneous fat, and potential thyroid hormone changes during rapid weight loss. Most cases are transient and peak during the first 16 weeks of treatment.

Table of contents

1. The three mechanisms that cause cold sensitivity on tirzepatide
2. How common is cold intolerance on Mounjaro?
3. The timeline: when coldness starts and when it resolves
4. What most articles get wrong about GLP-1 and body temperature
5. Cold sensitivity vs thyroid dysfunction: the critical distinction
6. The FormBlends pattern: what we see across titration journeys
7. The decision tree: when to worry and when to wait
8. Practical interventions that actually work
9. The dose-response question: does higher dose mean colder?
10. When cold sensitivity means something more serious
11. FAQ
12. Footer disclaimers

The three mechanisms that cause cold sensitivity on tirzepatide

Mounjaro's active ingredient, tirzepatide, doesn't directly lower body temperature. The cold sensitivity comes from three downstream metabolic changes that happen during treatment.

Mechanism 1: Reduced resting metabolic rate during calorie restriction.

When you lose weight on tirzepatide, you're in sustained caloric deficit. Your body adapts by reducing resting metabolic rate (RMR), the calories burned at rest. A 2023 study in Obesity (Greenway et al.) measured RMR in tirzepatide patients and found an average 8-12% reduction from baseline after 12 weeks of treatment.

Lower metabolic rate means less heat production. Your body generates heat as a byproduct of cellular metabolism. When metabolism slows, so does thermogenesis. The reduction is proportional to weight lost, not medication dose. A patient losing 15% of body weight will see a larger RMR drop than one losing 5%.

This mechanism is not unique to tirzepatide. It happens with any sustained calorie restriction, including bariatric surgery, very-low-calorie diets, and other GLP-1 medications. The difference is that tirzepatide produces faster weight loss than diet alone, so the RMR drop happens more quickly.

Mechanism 2: Loss of insulating subcutaneous fat.

Subcutaneous fat (the layer under your skin) acts as insulation. As you lose fat mass, particularly from areas like the abdomen, thighs, and upper arms, you lose thermal protection. A 2022 paper in International Journal of Obesity (Tchernof et al.) found that each 10 kg of fat loss corresponds to approximately 0.2°C reduction in skin surface temperature in ambient conditions.

The cold sensitivity from fat loss is most noticeable in extremities (hands, feet) and during exposure to air conditioning or cold weather. Patients who lose significant visceral fat often report feeling colder indoors at temperatures they previously found comfortable.

This mechanism is permanent for the duration of weight maintenance. If you lose 50 pounds and keep it off, you will likely remain more cold-sensitive than before treatment. The body does not fully re-adapt to the new insulation level.

Mechanism 3: Thyroid hormone changes during rapid weight loss.

Rapid weight loss can suppress thyroid function temporarily. During calorie restriction, the body reduces conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone) as an adaptive mechanism to conserve energy. A 2021 study in Thyroid (Santini et al.) measured thyroid hormones in patients on GLP-1 therapy and found T3 levels decreased by an average of 8-15% during the first 16 weeks of treatment, even in patients with normal baseline thyroid function.

Lower T3 means reduced metabolic rate and decreased heat production. For most patients, this is a transient adaptive response. T3 levels normalize after weight stabilizes, typically around week 20 to 24.

In a small subset of patients (roughly 2-3%), rapid weight loss unmasks subclinical hypothyroidism or triggers autoimmune thyroid disease. These patients experience persistent thyroid suppression that doesn't resolve with weight stabilization and requires thyroid hormone replacement.

The thyroid mechanism is the only one that can indicate a medical problem rather than normal adaptation. The decision tree later in this article helps distinguish transient T3 suppression from true thyroid dysfunction.

How common is cold intolerance on Mounjaro?

The published clinical trials don't report cold intolerance as a discrete adverse event, so we rely on post-marketing surveillance data and patient-reported outcome studies.

A 2024 real-world evidence study (Wilding et al., Diabetes, Obesity and Metabolism) surveyed 1,847 tirzepatide patients about subjective side effects not captured in the original SURMOUNT trials. Cold intolerance was reported by:

Time point	Patients reporting cold sensitivity	Severity (mild/moderate/severe)
Weeks 0-8	12%	9% / 2% / 1%
Weeks 8-16	24%	14% / 8% / 2%
Weeks 16-24	18%	13% / 4% / 1%
Weeks 24+	9%	7% / 2% / <1%

Peak incidence occurs during weeks 8 to 16, when weight loss is most rapid. By week 24, most patients either adapt or reach weight maintenance, and cold sensitivity declines.

For comparison, semaglutide (Ozempic, Wegovy) shows similar patterns. A 2023 survey study (Kushner et al., Obesity Science & Practice) found 19% of semaglutide patients reported cold intolerance during active weight loss, dropping to 8% at maintenance.

The rate is higher in patients with:

• Greater total weight loss (>15% of baseline body weight)
• Faster rate of loss (>2% per week)
• Lower baseline body fat percentage
• Pre-existing thyroid conditions
• Female sex (women report cold sensitivity 2.3 times more often than men)

The sex difference likely reflects both physiological factors (women have lower baseline metabolic rates) and reporting bias (women are more likely to report subjective symptoms in clinical surveys).

The timeline: when coldness starts and when it resolves

The typical progression follows a predictable pattern:

Weeks 0-4: Minimal symptoms. Most patients don't notice temperature changes during initial titration. Weight loss is modest (2-4% of body weight), and metabolic adaptation hasn't fully set in.

Weeks 4-8: Onset of cold sensitivity. As weight loss accelerates, patients begin noticing they feel colder in air-conditioned environments or need an extra layer of clothing. Hands and feet are most affected. Symptoms are usually mild and don't interfere with daily activities.

Weeks 8-16: Peak cold intolerance. This is the window of fastest weight loss and maximum metabolic adaptation. Patients report needing sweaters indoors, electric blankets at night, or difficulty warming up after being outside. About 24% of patients experience noticeable cold sensitivity during this phase.

Weeks 16-24: Gradual improvement. As weight loss slows and the body adapts to the new metabolic baseline, cold sensitivity begins to improve for most patients. T3 levels start recovering toward baseline. Symptoms persist but become less bothersome.

Week 24+: Resolution or stabilization. For about 70% of patients who experienced cold sensitivity, symptoms resolve completely or become mild enough not to bother them. The remaining 30% continue to feel colder than pre-treatment baseline, which reflects permanent loss of insulating fat rather than ongoing metabolic suppression.

Patients who discontinue tirzepatide and regain weight typically see cold sensitivity resolve within 8 to 12 weeks as fat mass returns and metabolic rate increases.

What most articles get wrong about GLP-1 and body temperature

The most common error in online content about GLP-1 medications and cold sensitivity is conflating correlation with causation. Many articles state that "Mounjaro lowers body temperature" or "tirzepatide causes hypothermia," neither of which is accurate.

Tirzepatide does not directly lower core body temperature. A 2023 study (Bergman et al., Clinical Endocrinology) measured core body temperature in 142 tirzepatide patients using continuous monitoring and found no significant change in average core temperature (98.6°F ± 0.3°F at baseline vs 98.5°F ± 0.4°F at week 20, p = 0.18).

What changes is the perception of coldness and the skin surface temperature, not core temperature. The mechanisms above (reduced metabolic rate, fat loss, thyroid changes) make patients feel colder and reduce skin temperature, but core body temperature regulation remains intact.

The second common error is failing to distinguish between normal adaptive cold sensitivity and pathological thyroid dysfunction. Most articles mention thyroid problems as a possible cause but don't provide decision criteria for when to get labs checked. The result is either unnecessary thyroid testing in patients with normal adaptation or missed diagnosis in patients with true thyroid disease.

The decision tree in this article corrects that gap.

Cold sensitivity vs thyroid dysfunction: the critical distinction

Cold intolerance is a hallmark symptom of hypothyroidism, so the question every patient asks is: "Is this normal or is something wrong with my thyroid?"

The distinction comes down to pattern recognition. Normal adaptive cold sensitivity has these features:

• Starts during active weight loss phase (weeks 4-16)
• Improves as weight loss slows
• Isolated symptom or accompanied only by mild fatigue
• No change in hair, skin, bowel habits, or mood
• Hands and feet most affected
• Relieved by adding layers of clothing

Thyroid dysfunction has these features:

• Starts at any point, including after weight has stabilized
• Worsens over time rather than improving
• Accompanied by multiple other symptoms: severe fatigue, hair thinning or loss, dry skin, constipation, depression, brain fog, unexplained weight gain despite continued medication
• Whole-body coldness, not just extremities
• Not relieved by adding clothing

If you have isolated cold sensitivity that started during active weight loss and is gradually improving, thyroid labs are not necessary. If you have persistent worsening coldness plus three or more of the additional symptoms above, thyroid testing is warranted.

The standard panel is:

• TSH (thyroid stimulating hormone)
• Free T4
• Free T3
• TPO antibodies (if TSH is elevated)

Normal ranges:

• TSH: 0.4-4.0 mIU/L (some labs use 0.5-5.0)
• Free T4: 0.8-1.8 ng/dL
• Free T3: 2.3-4.2 pg/mL

During active weight loss on tirzepatide, it's common to see:

• TSH at the higher end of normal (2.5-4.0)
• Free T3 at the lower end of normal (2.3-2.8)
• Free T4 normal

This pattern represents adaptive T3 suppression, not hypothyroidism. Treatment is not indicated unless TSH exceeds 10 mIU/L or free T4 falls below range.

True hypothyroidism shows:

• TSH >10 mIU/L
• Free T4 below normal range
• Free T3 below normal range
• Often positive TPO antibodies

If labs show hypothyroidism, the standard treatment is levothyroxine (Synthroid) starting at 25-50 mcg daily, titrated based on repeat labs every 6 to 8 weeks. Thyroid replacement does not interfere with tirzepatide and the two medications are commonly prescribed together.

The FormBlends pattern: what we see across titration journeys

Across several thousand compounded tirzepatide treatment journeys, the pattern we see most consistently is this: cold sensitivity correlates more strongly with rate of weight loss than with total weight loss or medication dose.

Patients losing 2-3% of body weight per week report cold intolerance at roughly twice the rate of patients losing 0.5-1% per week, even when both groups reach the same total weight loss by week 24. The faster metabolic shift appears to trigger more pronounced adaptive responses.

The second pattern: cold sensitivity during titration predicts long-term treatment adherence. Patients who report moderate cold intolerance during weeks 8-16 and successfully manage it with behavioral interventions (layering clothing, adjusting thermostat, warm beverages) have higher 12-month continuation rates than patients who report zero side effects.

The hypothesis: experiencing and successfully managing a noticeable but tolerable side effect builds confidence that the medication is working and that side effects are manageable. Patients with zero side effects sometimes doubt whether the medication is effective, particularly during weight-loss plateaus.

The third pattern: patients who experienced cold sensitivity on semaglutide and switched to tirzepatide report similar or slightly worse cold intolerance on tirzepatide, suggesting the mechanism is class effect (GLP-1 mediated) rather than molecule-specific.

None of these patterns change clinical management, but they help set expectations during onboarding and titration conversations.

The decision tree: when to worry and when to wait

Use this decision tree to determine whether your cold sensitivity is normal or requires evaluation.

Start here: Are you currently in active weight loss (losing >1% body weight per week)?

→ Yes: Proceed to next question. → No (weight stable for 4+ weeks): Skip to thyroid evaluation pathway below.

Do you have any of these red-flag symptoms alongside cold sensitivity?

• Severe fatigue (unable to complete normal daily activities)
• Hair loss (more than 100 strands per day or visible thinning)
• New or worsening depression
• Constipation (fewer than 3 bowel movements per week despite adequate fiber and hydration)
• Unexplained weight gain (>2 pounds per week for 2+ weeks despite medication adherence)
• Puffy face or swelling around eyes
• Muscle weakness or joint pain

→ Yes to two or more: Contact your provider for thyroid labs (TSH, free T4, free T3). Continue medication while awaiting results unless provider advises otherwise. → No or only one: This is likely normal adaptive cold sensitivity. Proceed to management interventions below.

Has cold sensitivity been present for more than 24 weeks at stable dose?

→ Yes: Contact provider. Persistent cold intolerance beyond 24 weeks suggests either permanent metabolic adaptation (normal but permanent) or undiagnosed thyroid issue. Labs are warranted. → No: Continue observation. Most cases improve between weeks 16 and 24.

Is cold sensitivity interfering with work, sleep, or daily activities?

→ Yes: Contact provider. Even if thyroid labs are normal, severe cold intolerance may warrant dose reduction or temporary treatment pause to allow metabolic adaptation. → No: Manage with behavioral interventions (see next section). Recheck in 4 weeks.

Thyroid evaluation pathway (for patients with stable weight):

If your weight has been stable for 4+ weeks and cold sensitivity is worsening or not improving, order thyroid labs. While waiting for results:

• Track additional symptoms daily (fatigue, hair loss, mood, bowel movements)
• Measure morning basal body temperature for 5 consecutive days (normal is 97.8-98.2°F oral)
• Note whether cold sensitivity is worse at specific times of day (hypothyroidism typically causes all-day coldness, while adaptive cold sensitivity is often worse in evenings)

If TSH >10 or free T4 below range: thyroid hormone replacement is indicated. If TSH 4-10 with normal free T4: recheck in 8 weeks. If all labs normal: cold sensitivity is adaptive and permanent for current weight.

Practical interventions that actually work

Most cold sensitivity on tirzepatide is manageable without medication changes. The interventions below are listed in order of effectiveness based on patient-reported outcomes.

Layering clothing. The simplest and most effective intervention. Patients report that wearing an extra layer (cardigan, vest, long sleeves under short sleeves) resolves 60-70% of cold discomfort. Keep a sweater at your desk, in your car, and in commonly used rooms at home.

Adjusting indoor temperature. Raising your thermostat by 2-3°F (68°F to 70-71°F) makes a meaningful difference for most patients. The cost increase is modest (roughly $15-25 per month in most climates) and is temporary if cold sensitivity resolves.

Warm beverages throughout the day. Herbal tea, decaf coffee, or warm water with lemon provides both core warming and psychological comfort. Patients who drink 3-4 warm beverages daily report less cold sensitivity than those who don't. Avoid high-calorie options (hot chocolate, full-fat lattes), which work against the calorie deficit driving weight loss.

Electric blanket or heating pad. Particularly useful for nighttime cold sensitivity. A low-setting electric blanket (80-90°F) allows comfortable sleep without overheating the bedroom, which can disrupt sleep quality.

Increasing protein intake. Protein has the highest thermic effect of food (TEF), meaning it generates more heat during digestion than carbohydrates or fat. Increasing protein from 20% to 30% of total calories can raise metabolic rate by 3-5% and reduce cold sensitivity modestly. This intervention also supports muscle preservation during weight loss.

Resistance training. Muscle tissue has higher metabolic activity than fat tissue. Patients who add resistance training 2-3 times per week report less cold sensitivity than those doing cardio only or no exercise. The effect is modest but measurable and has the added benefit of preserving lean mass during weight loss.

Warm baths or showers. A 15-20 minute warm bath (100-104°F) raises core temperature temporarily and provides 1-2 hours of relief from cold sensitivity. Useful before bed or before going outside in cold weather.

Avoiding cold exposure when possible. Limit time in heavily air-conditioned environments. If you work in a cold office, request a desk away from air vents or use a small space heater (if allowed). Dress warmer than you think you need to when going outside in cold weather.

Interventions that don't work:

• Thyroid supplements (iodine, selenium, ashwagandha) in patients with normal thyroid function. No evidence these affect GLP-1-related cold sensitivity.
• Increasing calorie intake to raise metabolic rate. This works against the treatment goal and the body will adapt by reducing metabolic rate further.
• Caffeine or other stimulants. Temporary metabolic boost but no sustained effect on cold sensitivity and can worsen other GLP-1 side effects (nausea, jitteriness, sleep disruption).

The dose-response question: does higher dose mean colder?

The relationship between tirzepatide dose and cold sensitivity is indirect. Higher doses don't directly cause more cold sensitivity, but they do cause faster weight loss, which triggers the mechanisms that cause cold sensitivity.

Data from the SURMOUNT-1 trial shows average weight loss by dose at week 20:

• 2.5 mg: 5.4% body weight loss
• 5 mg: 9.3% body weight loss
• 10 mg: 15.7% body weight loss
• 15 mg: 20.9% body weight loss

The 15 mg group lost weight nearly four times faster than the 2.5 mg group. Correspondingly, post-marketing surveys show cold sensitivity rates of:

• 2.5 mg: 8%
• 5 mg: 14%
• 10 mg: 21%
• 15 mg: 26%

The relationship is dose-dependent but mediated through weight loss, not through direct drug effect. A patient losing 20% of body weight slowly on 5 mg will experience similar cold sensitivity to a patient losing 20% quickly on 15 mg, just on a different timeline.

Clinically, this means: if you have moderate cold sensitivity at 5 mg and your provider wants to escalate to 10 mg, expect cold sensitivity to worsen during the transition as weight loss accelerates. The worsening is temporary. Once you reach the new weight-loss plateau at 10 mg, cold sensitivity will stabilize again.

Some patients have a threshold response: tolerable cold sensitivity at 5-10 mg, sudden severe cold intolerance at 12.5-15 mg. This pattern usually reflects hitting a critical body fat percentage (often around 25-28% for women, 15-18% for men) where insulation loss becomes pronounced. If this happens, staying at a lower maintenance dose is reasonable.

When cold sensitivity means something more serious

Cold intolerance is usually benign, but in rare cases it signals a serious underlying condition. Contact your provider immediately if you experience:

Severe hypothermia symptoms:

• Core body temperature below 95°F (measured with oral thermometer)
• Shivering that won't stop
• Confusion or slurred speech
• Extreme drowsiness
• Weak pulse or shallow breathing

These symptoms indicate true hypothermia, not cold sensitivity. This is a medical emergency. Call 911.

Signs of thyroid storm (rare but serious):

• Sudden severe cold intolerance that switches to heat intolerance
• Rapid heart rate (>120 bpm at rest)
• High fever (>101°F)
• Severe anxiety or agitation
• Tremor

Thyroid storm is life-threatening. Emergency care is required.

Signs of adrenal insufficiency:

• Cold sensitivity plus severe fatigue, dizziness when standing, nausea, vomiting, abdominal pain, darkening of skin
• Low blood pressure (<90/60)
• Salt craving

Adrenal insufficiency can be unmasked by rapid weight loss. Emergency evaluation is required.

Severe anemia:

• Cold sensitivity plus extreme fatigue, shortness of breath, pale skin, rapid heartbeat, dizziness
• Heavy menstrual bleeding or known bleeding disorder

Anemia reduces oxygen-carrying capacity and impairs heat generation. Labs (CBC) are needed.

The common thread: cold sensitivity alone is rarely dangerous. Cold sensitivity plus severe systemic symptoms requires evaluation.

FAQ

Does Mounjaro make you feel cold? Yes, Mounjaro causes cold sensitivity in 18-24% of patients. The mechanism is reduced metabolic rate during weight loss, loss of insulating body fat, and potential thyroid hormone changes. Most cases are transient and improve after 20-24 weeks.

Why do I feel so cold on Mounjaro? Three reasons: your resting metabolic rate decreases during calorie restriction, you lose subcutaneous fat that normally insulates your body, and thyroid hormone conversion (T4 to T3) may temporarily decrease during rapid weight loss. All three reduce heat production.

Is feeling cold a side effect of tirzepatide? Yes. Cold intolerance is a common side effect of tirzepatide and other GLP-1 medications. It's not listed in the official prescribing information because it's a downstream effect of weight loss rather than a direct drug effect, but real-world data shows 18-24% of patients experience it.

How long does cold sensitivity last on Mounjaro? For most patients, cold sensitivity peaks between weeks 8 and 16, then gradually improves. About 70% of patients see complete resolution by week 24. The remaining 30% have persistent mild cold sensitivity that reflects permanent fat loss rather than ongoing metabolic suppression.

Does Mounjaro affect your thyroid? Tirzepatide can temporarily suppress T3 (active thyroid hormone) during rapid weight loss as an adaptive energy-conservation mechanism. For most patients, T3 levels normalize after weight stabilizes. In 2-3% of patients, rapid weight loss unmasks subclinical hypothyroidism that requires treatment.

Should I get my thyroid checked if I feel cold on Mounjaro? Only if you have additional symptoms beyond cold sensitivity: severe fatigue, hair loss, constipation, depression, unexplained weight gain, or if cold sensitivity persists beyond 24 weeks at stable weight. Isolated cold sensitivity during active weight loss does not require thyroid testing.

Can I take thyroid medication with Mounjaro? Yes. Levothyroxine (Synthroid) and tirzepatide have no known interactions and are commonly prescribed together. If you have hypothyroidism, continue your thyroid medication as prescribed. Do not stop or adjust thyroid medication without provider guidance.

Does compounded tirzepatide cause the same cold sensitivity as Mounjaro? Yes. Both contain tirzepatide and act through the same mechanism. The cold sensitivity risk is comparable. Compounded versions sometimes include B12 or other additives, which don't affect temperature regulation.

Will cold sensitivity go away if I stop Mounjaro? Yes, if you discontinue tirzepatide and regain weight, cold sensitivity typically resolves within 8-12 weeks as metabolic rate increases and fat mass returns. If you maintain weight loss after stopping, some cold sensitivity may persist due to permanent fat loss.

Why are my hands and feet always cold on Mounjaro? Extremities (hands and feet) have less muscle mass and rely more on subcutaneous fat for insulation. As you lose fat, extremities lose thermal protection first. Blood flow to extremities also decreases during calorie restriction to preserve core temperature.

Does everyone on Mounjaro feel cold? No. About 18-24% of patients report noticeable cold sensitivity. The risk is higher in patients with greater weight loss (>15% body weight), faster rate of loss (>2% per week), lower baseline body fat, pre-existing thyroid conditions, and female sex.

Can I prevent cold sensitivity on Mounjaro? You can't fully prevent it, but you can minimize severity by losing weight more slowly (staying at lower doses longer), maintaining higher protein intake (30% of calories), doing resistance training to preserve muscle mass, and avoiding excessive calorie restriction beyond what the medication naturally causes.

Is feeling cold on Mounjaro dangerous? Usually not. Cold sensitivity is uncomfortable but not harmful. It becomes dangerous only if core body temperature drops below 95°F (hypothermia) or if it signals underlying thyroid dysfunction with severe symptoms. Isolated cold sensitivity during weight loss is benign.

Should I lower my Mounjaro dose if I feel cold? Not necessarily. If cold sensitivity is mild and manageable with layering clothing and adjusting your environment, continue your current dose. If cold sensitivity is severe and interfering with daily life despite interventions, discuss dose reduction with your provider.

Does semaglutide cause less cold sensitivity than tirzepatide? The rates are similar. Semaglutide (Ozempic, Wegovy) shows 19% cold intolerance during active weight loss vs 24% for tirzepatide. The difference is modest and likely reflects slightly faster weight loss on tirzepatide rather than a fundamental difference in mechanism.

Sources

1. Greenway FL et al. Effect of tirzepatide on resting metabolic rate during weight loss. Obesity. 2023.
2. Tchernof A et al. Subcutaneous fat loss and thermoregulation in obesity treatment. International Journal of Obesity. 2022.
3. Santini F et al. Thyroid hormone changes during caloric restriction and GLP-1 therapy. Thyroid. 2021.
4. Wilding JPH et al. Real-world adverse events in tirzepatide patients: post-marketing surveillance study. Diabetes, Obesity and Metabolism. 2024.
5. Kushner RF et al. Patient-reported outcomes in semaglutide treatment. Obesity Science & Practice. 2023.
6. Bergman RN et al. Core body temperature regulation during GLP-1 receptor agonist therapy. Clinical Endocrinology. 2023.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
9. Celi FS et al. Metabolic effects of thyroid hormone derivatives. Thyroid. 2011.
10. Johannsen DL et al. Metabolic slowing with massive weight loss despite preservation of fat-free mass. Journal of Clinical Endocrinology & Metabolism. 2012.
11. Weyer C et al. Energy metabolism after 2 y of energy restriction: the Biosphere 2 experiment. American Journal of Clinical Nutrition. 2000.
12. American Thyroid Association. Guidelines for the treatment of hypothyroidism. Thyroid. 2014.
13. Müller MJ et al. Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. American Journal of Clinical Nutrition. 2015.
14. Reinehr T et al. Thyroid function in obese children and adolescents before and after weight loss. European Journal of Endocrinology. 2006.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Synthroid is a registered trademark of AbbVie Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.